Computational characterisation ofToxoplasma gondiiFabG (3-oxoacyl-[acyl-carrier-protein] reductase): a combined virtual screening and all-atom molecular dynamics simulation study


Aygun C., MUTLU Ö.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, vol.40, no.5, pp.1952-1969, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 5
  • Publication Date: 2022
  • Doi Number: 10.1080/07391102.2020.1834456
  • Journal Name: JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.1952-1969
  • Keywords: Toxoplasma gondii, 3-oxoacyl-[acyl-carrier-protein] reductase, FabG, structure-based drug design, fatty acid synthesis, FASII, CARRIER PROTEIN REDUCTASE, FATTY-ACID BIOSYNTHESIS, ENOYL-ACP REDUCTASE, TOXOPLASMA-GONDII, PLASMODIUM-FALCIPARUM, DRUG DISCOVERY, APICOPLAST, METABOLISM, SEQUENCE, CHAIN
  • Marmara University Affiliated: Yes

Abstract

Toxoplasma gondiiis an opportunistic obligate parasite, ubiquitous around the globe with seropositivity rates that range from 10% to 90% and infection by the parasite of pregnant women causes pre-natal death of the foetus in most cases and severe neurodegenerative syndromes in some. No vaccine is currently available, and since drug-resistance is common amongT. gondiistrains, discovering lead compounds for drug design using diverse tactics is necessary. In this study, the sole constituent isoform of an enzymatic 3-oxoacyl-[acyl-carrier-protein] reduction step in an apicoplast-located fatty acid biosynthesis pathway was chosen as a possible drug target. FASII is prokaryotic therefore, targeting it would pose fewer side-effects to human hosts. After a homology 3D modelling of TgFabG, a high-throughput virtual screening of 9867 compounds, the elimination of ligands was carried out by a flexible ligand molecular docking and 200 ns molecular dynamics simulations, with additional DCCM and PC plot analyses. Molecular Dynamics and related post-MD analyses of the top 3 TgFabG binders selected for optimal free binding energies, showed that L2 maintained strong H-bonds with TgFabG and facilitated structural reorientation expected of FabGs, namely an expansion of the Rossmann Fold and a flexible lid capping. The most flexible TgFabG sites were the alpha 7 helix (the flexible lid region) and the beta 4-alpha 4 and beta 5-alpha 6 loops. For TgFabG-L2, the movements of these regions toward the active site enabled greater ligand stability. Thus, L2 ("Skimmine"; PubChem ID: 320361), was ultimately selected as the optimal candidate for the discovery of lead compounds for rational drug design. Communicated by Ramaswamy H. Sarma